GGrantIndex
← Leaderboards

John L. Marshall

Georgetown University

Google Scholar ↗PubMed ↗ORCID ↗
$2,076,333
Attributed
$2,076,333
Total exposure
21
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $322.6K · FY2005–09
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$2,076,333 · 21

By mechanism

R01$1,465,467 · 1
M01$610,866 · 20

Top collaborators

No co-investigators on record.

Most similar at Georgetown University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyDrug Administration Rate /DurationPharmacokineticsDrug Screening /EvaluationAngiogenesis InhibitorsIntravenous AdministrationInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelSourceGrantPaclitaxelResourcesFundingUnited States National Institutes Of HealthAntitumor ResponseNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer VaccineResponseChemotherapy

Grant awards (32)

CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY$24,172
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY$99,168
M01 · FY2008 · RR · contact PI
A PHASE I OPEN LABEL SAFETY AND PHARMACOKINETIC STUDY OF SGT-53$1,428
M01 · FY2008 · RR · contact PI
VACCINIA-CEA(6D)TRICOM & FOWLPOX-CEA(6D)-TAXOTERE W/GM-CSF & DOCETAXEL$105,098
M01 · FY2007 · RR · contact PI
PH I: ORAL GLEEVEC & ONE HR WEEKLY PACLITAXEL INFUSION- METASTATICS SOLID TUMORS$52,549
M01 · FY2007 · RR · contact PI
PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY PACLITAXEL IN$14,302
M01 · FY2007 · RR · contact PI
TRICOM + TAXOTERE$10,806
M01 · FY2007 · RR · contact PI
PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY PACLITAXEL IN$119,776
M01 · FY2006 · RR · contact PI
TRICOM + TAXOTERE$89,471
M01 · FY2006 · RR · contact PI
CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA$296,595
R01 · FY2005 · CA
CALGB 89903: PH II OF ANTI-IDIOTYPE MONOCLONALANTIBODY VACCINE CEAVAC &TRIAB$13,103
M01 · FY2005 · RR
PHASE III: CHEMORADIATN AFTER GASTRIC RESECTN OR GASTROESOPHAGEAL ADENOCARCINOMA$9,707
M01 · FY2005 · RR
PHASE I CLINICAL TRIAL OF DAILY ORAL GLEEVEC (IMATINIB MESYLATE)$3,236
M01 · FY2005 · RR
CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA$296,595
R01 · FY2004 · CA
Daily oral Gleevec and 1hr weekly Paclitaxel infusion$68,050
M01 · FY2004 · RR
CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA$296,595
R01 · FY2003 · CA
CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA$296,595
R01 · FY2002 · CA
CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA$279,087
R01 · FY2001 · CA
Oral CEP-701 in Solid Tumors--Phase I Study$0
M01 · FY2000 · RR
TNP 470 and Taxol in Advanced Cancer--Phase I Study$0
M01 · FY2000 · RR
TNP 470 and Taxol in Advanced Cancer--Phase I Study$0
M01 · FY2000 · RR
Depsipeptide in Patients with Advanced Cancer$0
M01 · FY2000 · RR
Depsipeptide in Patients with Advanced Cancer$0
M01 · FY2000 · RR
Bryostatin by Intravenous Infusion in Advanced Cancer$0
M01 · FY2000 · RR
Bryostatin by Intravenous Infusion in Advanced Cancer$0
M01 · FY2000 · RR
MSI-1256F (Squalamine Lactate)--Safety, Tolerance, Pharmacokinetics$0
M01 · FY2000 · RR
MSI-1256F (Squalamine Lactate)--Safety, Tolerance, Pharmacokinetics$0
M01 · FY2000 · RR
Bryostatin and Cisplatin in Advanced Cancer--Phase I$0
M01 · FY2000 · RR
Bryostatin and Cisplatin in Advanced Cancer--Phase I$0
M01 · FY2000 · RR
TNP-470 120 Hour Continuous Infusion in Advanced Cancer$0
M01 · FY2000 · RR
TNP-470 120 Hour Continuous Infusion in Advanced Cancer$0
M01 · FY2000 · RR
Oral CEP-701 in Solid Tumors--Phase I Study$0
M01 · FY2000 · RR